Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats

Journal of the Formosan Medical Association

Volumn 113, Issue 12, 2014, Pages 921-928

  Kukkar, Ankesh ^a   Singh, Nirmal ^a   Jaggi, Amteshwar Singh ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Chronic constriction injury; Inflammation; Neuropathic pain; Sciatic nerve ligation; Sodium butyrate

Indexed keywords

BIOLOGICAL MARKER; BUTYRIC ACID; TUMOR NECROSIS FACTOR ALPHA; ANTIHISTAMINIC AGENT; HISTONE DEACETYLASE INHIBITOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC CONSTRICTION INJURY; CONTROLLED STUDY; HOT PLATE TEST; HYPERALGESIA; NEUROPATHIC PAIN; NONHUMAN; RAT; SCIATIC NERVE; VON FREY TEST; ANIMAL; COMPLICATION; DISEASE MODEL; FEMALE; MALE; METABOLISM; NERVE COMPRESSION; NEURALGIA; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE ANTAGONISTS; HISTONE DEACETYLASE INHIBITORS; HYPERALGESIA; MALE; NERVE COMPRESSION SYNDROMES; NEURALGIA; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918809111     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.05.013     Document Type: Article

References (50)

1. Jaggi A.S., Singh N. Role of different brain areas in peripheral nerve injury-induced neuropathic pain. Brain Res 2011, 1381:187-201.
2. Vranken J.H. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009, 1:71-78.
3. Zupkovitz G., Tischler J., Posch M., Sadzak I., Ramsauer K., Egger G., et al. Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol 2006, 21:7913-7928.
4. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and coregulates major cellular functions. Science 2009, 325:834-840.
5. Skov V., Larsen T.S., Thomassen M., Riley C.H., Jensen M.K., Bjerrum O.W., et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasm's. Leuk Lymphoma 2012, 53:123-129.
6. Kawabata T., Nishida K., Takasugi K., Ogawa H., Sada K., Kadota Y., et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R133.
7. Marshall G.M., Gherardi S., Xu N., Neiron Z., Trahair T., Scarlett C.J., et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc induced oncogenic effects. Oncogene 2010, 29:5957-5968.
8. Hancock W.W., Akimova T., Beier U.H., Liu Y., Wang L. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 2012, 71(Suppl. 2):i46-i54.
9. Chung Y.L., Lee M.Y., Wang A.J., Yao L.F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2013, 8:707-717.
10. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008, 7:854-868.
11. Shein N.A., Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med 2011, 17:448-456.
12. Tochiki K.K., Cunningham J., Hunt S.P., Géranton S.M. The expression of spinal methylCpG binding protein 2, DNA methyltransferases and histone deacetylases is modulated in persistent pain states. Mol Pain 2012, 8:14.
13. Bai G., Wei D., Zou S., Ren K., Dubner R. Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia. Mol Pain 2010, 6:51.
14. Rodriguez-Menendez V., Tremolizzo L., Cavaletti G. Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?. Curr Cancer Drug Targets 2008, 8:266-274.
15. Cousens L.S., Gallwitz D., Alberts B.M. Different accessibilities in chromatin to histone acetylase. J Biol Chem 1979, 254:1716-1723.
16. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 2010, 107:6532-6537.
17. Muthuraman A., Jaggi A.S., Singh N., Singh D. Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine induced painful neuropathy in rats. Eur J Pharmacol 2008, 587:104-111.
18. Maves T.J., Pechman P.S., Gebhart G.F., Meller S.T. Possible chemical contribution from chromic gut sutures produces disorders of pain sensation like those seen in man. Pain 1993, 54:57-69.
19. Flatters S.J., Bennett G.J. Ethosuximide reverses paclitaxel- and vincritine-induced painful peripheral neuropathy. Pain 2004, 109:150-161.
20. Erichsen H.K., Blackburn-Munro G. Pharmacological characterization of the spared nerve injury model of neuropathic pain. Pain 2002, 98:151-161.
21. Jain V., Jaggi A.S., Singh N. Ameliorative potential of rosiglitazone in tibial and sural nerve transection-induced painful neuropathy in rats. Pharmacol Res 2009, 59:385-392.
22. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63.
23. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. J Biol Chem 1951, 193:265-275.
24. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1998, 33:87-107.
25. Jaggi A.S., Jain V., Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol 2011, 25:1-28.
26. Jin Y., Sato J., Yamazaki M., Omura S., Funakubo M., Senoo S., et al. Changes in cardiovascular parameters and plasma norepinephrine level in rats after chronic constriction injury on the sciatic nerve. Pain 2008, 135:221-231.
27. Jaggi A.S., Singh N. Exploring the potential of telmisartan in chronic constriction injury- induced neuropathic pain in rats. Eur J Pharmacol 2011, 667:215-221.
28. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007, 321:892-901.
29. Zhang L., Jin S., Wang C., Jiang R., Wan J. Histone deacetylase inhibitors attenuate acute lung injury during cecal ligation and puncture-induced polymicrobial sepsis. World J Surg 2010, 34:1676-1683.
30. Leung L., Cahill C.M. TNF-alpha and neuropathic pain - a review. J Neuroinflammation 2010, 7:27.
31. Muthuraman A., Singh N. Neuroprotective effect of saponin rich extract of Acorus calamus L. in rat model of chronic constriction injury (CCI) of sciatic nerve-induced neuropathic pain. J Ethnopharmacol 2012, 142:723-731.
32. Jaggi A.S., Singh N. Differential effect of spironolactone in chronic constriction injury and vincristine-induced neuropathic pain in rats. Eur J Pharmacol 2010, 648:102-109.
33. Kukkar A., Singh N., Jaggi A.S. Neuropathic pain-attenuating potential of aliskiren in chronic constriction injury model in rats. J Renin Angiotensin Aldosterone Syst. 2013, 14:116-123.
34. Gong D., Geng C., Jiang L., Aoki Y., Nakano M., Zhong L. Effect of pyrroloquinoline quinone on neuropathic pain following chronic constriction injury of the sciatic nerve in rats. Eur J Pharmacol 2012, 697:53-58.
35. Amin B., Hajhashemi V., Hosseinzadeh H., Abnous K.H. Antinociceptive evaluation of ceftriaxone and minocycline alone and in combination in a neuropathic pain model in rat. Neuroscience 2012, 224:15-25.
36. Sacerdote P., Franchi S., Trovato A.E., Valsecchi A.E., Panerai A.E., Colleoni M. Transient early expression of TNF-alpha in sciatic nerve and dorsal root ganglia in a mouse model of painful peripheral neuropathy. Neurosci Lett 2008, 436:210-213.
37. Uçeyler N., Tscharke A., Sommer C. Early cytokine gene expression in mouse CNS after peripheral nerve lesion. Neurosci Lett 2008, 436:259-264.
38. Foster S.J., McCormick L.M., Ntolosi B.A., Campbell D. Production of TNF alpha by LPS-stimulated murine, rat and human blood and its pharmacological modulation. Agents Actions 1993, 38:C77-C79.
39. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines invitro and systemic inflammation invivo. Mol Med 2005, 11:1-15.
40. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Nat Acad Sci USA 2002, 99:2995-3000.
41. Grabiec A.M., Reedquist K.A. Histone deacetylases in RA: epigenetics and epiphenomena. Arthritis Res Ther 2010, 12:14.
42. Joosten L.A., Leoni F., Meghji S., Mascagni P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med 2011, 17:391-396.
43. Segain J.P., Raingeard de la Blétière D., Bourreille A., Leray V., Gervois N., Rosales C. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000, 47:397-403.
44. Usami M., Kishimoto K., Ohata A., Miyoshi M., Aoyama M., Fueda Y., et al. Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr Res 2008, 28:321-328.
45. Place R.F., Noonan E.J., Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 2005, 70:394-406.
46. Zhang Z., Cai Y.Q., Zou F., Bie B., Pan Z.Z. Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med 2011, 17:1448-1455.
47. Moore K.A., Kohno T., Karchewski L.A., Scholz J., Baba H., Woolf C.J. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci 2002, 22:6724-6731.
48. Munro G., Ahring P.K., Mirza N.R. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009, 30:453-459.
49. Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005, 25:3219-3228.
50. Stück E.D., Christensen R.N., Huie J.R., Tovar C.A., Miller B.A., Nout Y.S., et al. Tumor necrosis factor alpha mediates GABA (A) receptor trafficking to the plasma membrane of spinal cord neurons invivo. Neural Plast 2012, 2012:261345. 10.1155/2012/261345.